AstraZeneca Signs on as First Partner for BioWisdom's Toxicity Safety Program
Jul 02, 2007
NEW YORK (GenomeWeb News) - AstraZeneca has signed a three-year agreement for BioWisdom’s Safety Intelligence Program, an initiative to develop an “intelligence system” to analyze drug safety and toxicity data for use in drug discovery and development.
BioWisdom said AstraZeneca is its first partner for the program, and as such takes a place on the firm’s SIP advisory board.
The SIP program will support development of methods for identifying and analyzing toxicities, characterizing mechanisms of protein targets with toxic effects, predicting and evaluating potential toxicity issues, comparing species for animal models, and planning and designing clinical trials, BioWisdom said.